Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective

Abstract Objectives: To determine the cost-effectiveness of omalizumab compared with routine clinical practice in the treatment and control of severe persistent asthma. Methods: Cost-effectiveness analysis using pre- and post-treatment with omalizumab after 10 months of 47 patients diagnosed with un...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of asthma 2015-03, Vol.52 (2), p.205-210
Main Authors: Levy, Alberto Nahon, García a Ruiz, Antonio J., García-Agua Soler, Nuria, Sanjuan, María Victoria Hidalgo
Format: Article
Language:English
Subjects:
Adult
Aged
Anti-Asthmatic Agents - economics
Anti-Asthmatic Agents - therapeutic use
Antibodies, Anti-Idiotypic - economics
Antibodies, Anti-Idiotypic - therapeutic use
Antibodies, Monoclonal, Humanized - economics
Antibodies, Monoclonal, Humanized - therapeutic use
Asthma
Asthma - drug therapy
Cost-Benefit Analysis
cost-utility
effectiveness
Emergency Service, Hospital - economics
Emergency Service, Hospital - statistics & numerical data
Female
healthcare costs
Humans
Male
Middle Aged
Omalizumab
Quality of Life
Quality-Adjusted Life Years
Respiratory Function Tests
Severity of Illness Index
Spain
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives: To determine the cost-effectiveness of omalizumab compared with routine clinical practice in the treatment and control of severe persistent asthma. Methods: Cost-effectiveness analysis using pre- and post-treatment with omalizumab after 10 months of 47 patients diagnosed with uncontrolled severe persistent asthma attended by the Pneumology Service, Hospital Universitario Virgen de la Victoria, Malaga. Effectiveness was assessed by the number of emergency room (ER) visits for exacerbations and quality-adjusted life years (QALY) gained. The costs of treatment with omalizumab and ER visits were analyzed using the National Health System perspective. Results are expressed in cost per QALY gained and cost per ER visit avoided (costs €2012). Results: Exacerbations with ER visits decreased significantly (p 
ISSN:0277-0903
1532-4303
DOI:10.3109/02770903.2014.941474